RIST: A potent new combination therapy for glioblastoma

International Journal of Cancer

Volumn 136, Issue 4, 2015, Pages E173-E187

  Nonnenmacher, Lisa ^a   Westhoff, Mike Andrew ^a   Fulda, Simone ^a,b   Karpel Massler, Georg ^a   Halatsch, Marc Eric ^a   Engelke, Jens ^a   Simmet, Thomas ^d   Corbacioglu, Selim ^a,c   Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

Glioblastoma; Orthotopic mouse model; RIST therapy

Indexed keywords

IRINOTECAN; PICTILISIB; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; RAPAMYCIN; SUNITINIB; TEMOZOLOMIDE; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DACARBAZINE; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAPILLARY DENSITY; CELL COUNT; CELL VIABILITY; CHILD; CONTROLLED STUDY; DIARRHEA; DOWN REGULATION; DRUG DISTRIBUTION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATIENT COMPLIANCE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SCHOOL CHILD; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR VOLUME; UPREGULATION; ADOLESCENT; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULARLY TARGETED THERAPY; NONOBESE DIABETIC MOUSE; TUMOR CELL LINE;

ADOLESCENT; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; CHILD; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; INDOLES; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE, INBRED NOD; MOLECULAR TARGETED THERAPY; PYRROLES; SIROLIMUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918817033     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29138     Document Type: Article

References (42)

1. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012;107:359-64
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
3. Pourquier P, Waltman JL, Urasaki Y, et al. Topoisomerase I-mediated cytotoxicity of N-methyl-Nmitro- N-mitrosoguanidine: Trapping of topoisomerase I by the O6-methylguanine. Cancer Res 2001;61:53-8
4. Reardon DA, Quinn JA, Rich JN, et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 2005; 104:1478-86
5. Quinn JA, Jiang SX, Reardon DA, et al. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol 2009;95:393-400
6. Hammerman PS, Lawrence MS, Voet D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8
7. Fan QW, Weiss WA. Targeting the RTK-PI3KmTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol 2010; 347: 279-96
8. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003;63:4009-16
9. De Boüard S, Herlin P, Christensen JG, et al. Antiangiogenic and antiinvasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007;9:412-23
10. Pan E, Yu D, Yue B, et al. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J Neurooncol 2012;110:111-18
11. Corbacioglu S, Kilic M, Westhoff MA, et al. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligandindependent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 2006;108:3504-13
12. Heimberger AB, Wang E, McGary EC, et al. Mechanisms of action of rapamycin in gliomas. Neuro Oncol 2005;7:1-11
13. Opel D, Westhoff MA, Bender A, et al. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 2008;68: 6271-80
14. Akhavan D, Cloughesy TF, Mischel PS. mTOR signaling in glioblastoma: Lessons learned from bench to bedside. Neuro Oncol 2010;12:882-9
15. Koul D, Shen R, Kim YW, et al. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 2010; 12:559-69
16. Westhoff MA, Kandenwein JA, Karl S, et al. The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene 2009;28: 3586-96
17. Vellanki SH, Grabrucker A, Liebau S, et al. Small-molecule XIAP inhibitors enhance gammairradiation- induced apoptosis in glioblastoma. Neoplasia 2009;11:743-52
18. Westhoff MA, Zhou S, Bachem MG, et al. Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene 2008;27:5169-81
19. Westhoff MA, Zhou S, Nonnenmacher L, et al. Inhibition of NF-jB signaling ablates the invasive phenotype of glioblastoma. Mol Cancer Res 2013; 11:1611-23
20. Nicoletti I, Migliorati G, Pagliacci MC, et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139: 271-9
21. Karpel-Massler G, Westhoff MA, Kast RE, et al. Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. Anticancer Agents Med Chem 2014;14: 313-18
22. Fulda S, Sieverts H, Friesen C, et al. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997;57: 3823-9
23. Giagkousiklidis S, Vogler M, Westhoff MA, et al. Sensitization for gamma-irradiationinduced apoptosis by second mitochondria derived activator of caspase. Cancer Res 2005;65: 10502-13
24. Fulda S, Wick W, Weller M, et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer druginduced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8:808-15
25. Clark MJ, Homer N, O'Connor BD, et al. U87- MG decoded: The genomic sequence of cytogenetically aberrant human cancer cell line. PLoS Genet 2010;6:1000832
26. Chahal M, Xu Y, Lesniak D, et al. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol 2010;12:822-33
27. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-40
28. Alao JP. The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007;6:24
29. Gartel AL, Radhakrishnan SK. Lost in transcription: P21 repression, mechanisms, and consequences. Cancer Res 65;10:3980-5
30. Abbas T, Dutta A. p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-14
31. Alt JR, Gladden AB, Diehl JA. p21Cip1 Promotes Cyclin D1 Nuclear Accumulation via Direct Inhibition of Nuclear Export. J Biol Chem 2002;277: 8517-8523
32. Raynaud FI, Eccles SA, Patel S, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: From PI-103 through PI- 540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 2009;8:1725-38
33. Qayum N, Im J, Stratford MR, et al. Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo. Clin Cancer Res 2012;18:161-9
34. Zhou Q, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol 2009;11:301-10
35. Matsumoto S, Batra S, Saito K, e al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res 2011;71:6350-9
36. Edgar KA, Wallin JJ, Berry M, et al. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res 2010; 70:1164-72
37. Junttila TT, Akita RW, Parsons K, et al. Ligandindependent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009;15:429-40
38. Bruyère C, Abeloos L, Lamoral-Theys D, et al. Temozolomide modifies caveolin-1 expression in experimental malignant gliomas in vitro and in vivo. Transl Oncol 2011;4:92-100.
39. Canu B, Fioravanti A, Orlandi P, et al. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia 2011;13:217-29
40. Saito K, Matsumoto S, Yasui H, et al. Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin. PLoS One 2012;7:e49456
41. MacDonald TJ, Aguilera D, Kramm CM Treatment of high-grade glioma in children and adolescents. Paediatric and adult glioblastoma: Multiform (epi)genomic culprits emerge. Neuro Oncol 2011;13:1049-58
42. Sturm D, Bender S, Jones DT, et al. Pediatric and adult glioblastoma: Multiform (epi)genomic culprits emerge. Nat Rev Cancer 2014;14:92-107.